Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.1B
13M shares
52-week range
$67.84 – $107.90
37% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
P/S (TTM)
12.3
EV / FCF (TTM)
40.3
iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.
www.iradimed.comNo one on the platform currently holds IRMD.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 440,712 | $42.4M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-08-14 | $0.2000 | 2026-08-28 |
| 2026-05-15 | $0.2000 | 2026-05-29 |
| 2026-02-23 | $0.2000 | 2026-03-06 |
| 2025-12-17 | $0.5000 | 2025-12-30 |
| 2025-11-14 | $0.1700 | 2025-11-25 |
| 2025-08-18 | $0.1700 | 2025-08-28 |
| 2025-05-20 | $0.1700 | 2025-05-30 |
| 2025-02-24 | $0.1700 | 2025-03-05 |
| 2024-11-15 | $0.1500 | 2024-11-25 |
| 2024-08-20 | $0.1500 | 2024-08-30 |
No one on the platform has traded IRMD yet.
| 2024-05-17 | $0.1500 | 2024-05-30 |
| 2023-12-21 | $0.4800 | 2024-01-12 |
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 47.7% | 61.5% | — | — | — | |
| Rev. Growth % | 14.4% | 21.5% | ||||
| Profit Margin % | 26.8% | 25.1% | 20.0% | |||
| Free Cash Flow Margin % | 20.5% | 18.7% | 19.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +6.6% on the P/E track.
At today's price, your expected annual return is +11.3% on the P/E track.
At today's price, your expected annual return is +15.5% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $91M | +10.3% | $2.09 | $2.01–$2.16 | 39.5× | 1 |
| 2027 | $101M | +10.7% | $2.41 | $2.40–$2.42 | 34.3× | 1 |
| 2028 | $113M | +11.7% | $2.71 | $2.70–$2.72 | 30.5× | 1 |
| 2029 | $132M | +16.9% | $3.04 | $3.03–$3.05 | 27.2× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-31 | $0.44 | $0.46 | +4.5% |
| 2026-05-01 | $0.45 | $0.49 | +8.9% |
| 2026-02-10 | $0.49 | $0.54 | +10.2% |
| 2025-11-03 | $0.48 | $0.47 | -2.1% |
| 2025-08-01 | $0.45 | $0.49 | +8.9% |
| 2025-05-05 | $0.43 | $0.42 | -2.3% |
| 2025-02-13 | $0.45 | $0.44 | -2.2% |
| 2024-10-31 | $0.39 |
| $0.43 |
| +10.3% |
| $572M |
| — |
| GDRXGoodRx Holdings, Inc. | $3.39 | -2.87% | $1.2B | — |
| IARTIntegra LifeSciences Holdings Corporation | $16.06 | +2.36% | $1.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
bot $COCO at 53.70; bot $IRMD at 84.73; bot $YOU at 43.40;
View on StockTwits ↗
https://www.marketbeat.com/earnings/reports/2026-7-31-iradimed-co-stock/ $IRMD iRadimed Earnings Transcript
View on StockTwits ↗
$IRMD Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.41 down -8.89% YoY • Reported revenue of $20.47M up 0.28% YoY • For the third quarter of 2026, Iradimed expects revenue of $23.0 million to $24.5 million, GAAP diluted earnings per share of $0.49 to $0.54, and non-GAAP diluted earnings per share of $0.54 to $0.59.
View on StockTwits ↗
@Kingspellchecker Yep, looks like a low likelihood of an out right sale of $IRMD . The synergy is t there. Most outcomes point to a partnership or lease agreement. I recall mentions of $APPL interest in $GSAT and possibly a 2nd company to aid in the D2C plan. I always thought it was alluding to $IRDM . More consolidation is a must, if not $IRDM who? thoughts? Note: $AAPLX.X vs $APPL what the heck is $APPLX what did I miss? Ticker change?
View on StockTwits ↗
$IRMD Share Price: $96.52 Contract Selected: Jan 15, 2027 $95 Calls Buy Zone: $11.32 – $13.99 Target Zone: $21.54 – $26.32 Potential Upside: 80% ROI Time to Expiration: 218 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗
Final Trade: IRMD, GDX, DELL, SLG $irmd $gdx $dell $slg https://www.cnbc.com/video/2026/05/29/final-trade-irmd-gdx-dell-slg.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
View on StockTwits ↗$IRMD Q1 '26 Earnings Results & Recap Iradimed reaffirms full-year 2026 guidance with expected revenue of $91.0 million to $96.0 million, GAAP diluted EPS of $1.90 to $2.05, and non-GAAP diluted EPS of $2.06 to $2.21.
View on StockTwits ↗
$IRMD out of the tightness give YO a MRVLelous sign and all that JAZZ. 🐒🍌🧠⏰♾️
View on StockTwits ↗
5 medical instrument stocks flashing serious short-term upside 👀 $ISRG $GMED $EW $ALC $IRMD are getting attention as AI tools, acquisitions, and new product pipelines fuel growth expectations — a combo that often sparks momentum in this space. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2881459/5-medical-instruments-stocks-to-buy-amid-huge-short-term-price-upside?cid=sm-stocktwits-2-2881459-teaser-36722&ADID=SYND_STOCKTWITS_TWEET_2_2881459_TEASER_36722
View on StockTwits ↗Five medical instrument stocks with significant short-term potential! 🚀 🤖 $ISRG leads the charge with AI-driven innovations, boasting a Zacks Rank #1 and a short-term price target indicating a 26% increase from its last close, with an upside of up to 52%. 💼 $GMED strengthens its position with strategic mergers, a debt-free balance sheet, and a promising pipeline, marked by a Zacks Rank #1 and a short-term target of a 24.7% gain, with an upside of up to 40.1%. 💔 $EW is advancing its Structural Heart business, supported by a Zacks Rank #2 and a short-term price target increase of 14%, with a maximum upside of 30.5%. 👓 $ALC capitalizes on its Vision Care innovations, with a Zacks Rank #2 and a short-term target increase of 13.9%, with an upside of up to 36.8%. 🩺 $IRMD expands with MRI-compatible products, holding a Zacks Rank #2 and a forecasted 19.9% rise, with an upside of 20%. Explore the full growth story here 👉 https://www.zacks.com/stock/news/2881459/5-medical-instruments-stocks-to-buy-amid-huge-short-term-price-upside?cid=sm-stocktwits-2-2881459-body-36721&ADID=SYND_STOCKTWITS_TWEET_2_2881459_BODY_36721
View on StockTwits ↗
$IRMD iRadimed develops MRI-compatible medical devices. Growth depends on hospital capital spending. Margins benefit from niche positioning.
View on StockTwits ↗
$IRMD Current Stock Price: $100.55 Contracts to trade: $100.0 IRMD Feb 20 2026 Call Entry: $0.30 Exit: $0.52 ROI: 72% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗
Top 3 #momentum #stocks In The GorillaTrades #portfolio This Week: Amer Sports $AS +5.8%, Greenbrier $GBX +4.6%, and iRadimed $IRMD +4.6%
View on StockTwits ↗
$IRMD Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.51 up 24.39% YoY • Reported revenue of $22.69M up 17.03% YoY • Iradimed expects full year 2026 revenue between $91M and $96M, with GAAP diluted EPS in the range of $1.90 to $2.05. For Q1 2026, Iradimed anticipates revenue from $21M to $22M.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.